Skip to content

The application of carcinoma in radioactive labeling fibroblast activated protein inhibitor

The application of carcinoma in radioactive labeling fibroblast activated protein inhibitor

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200063441
Enrollment
Unknown
Registered
2022-09-06
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma

Interventions

Sponsors

Affiliated Hospital of Guilin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 90 Years

Inclusion criteria

Inclusion criteria: 1. Participants with newly diagnosed tumor; 2. Participants who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion criteria

Exclusion criteria: 1. Patients in critical emergency care, those with respiratory depression, (pulmonary) airway obstruction or tissue hypoxia; 2. Drug and/or alcohol abusers, allergic individuals; 3. Those who are unable to tolerate and cooperate with the examination; 4. Those who, in the judgement of the investigator, are unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
diagnostic performance;SUVmax, maximal Standardized Uptake Value;

Countries

China

Contacts

Public ContactXingyu Mu

Affiliated Hospital of Guilin Medical University

138887664@qq.com+86 13347631119

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 21, 2026